We welcome the political agreement reached on the pharma reform last night, which is a crucial step in boosting innovation and investment in the EU’s pharma sector.
The main aim of the new rules is to make sure that medicines in the EU are safe, effective and available to all patients in Europe.
Amongst other things, the rules will:
✅ Expand access & availability of medicines
✅ Accelerate medicine supply chains – by cutting red pate for companies and reducing evaluation times for new medicines by the @EMA.
✅ Place the EU at the forefront of pharmaceutical innovation – by offering world-leading incentives for innovative products.
✅ Allow for speedy market access for generic medicines
✅Address medicine shortages
The new rules are complemented by the Critical Medicines’ Act proposal, the recent Life Sciences Strategy and the upcoming Biotech Act.
Check out the factsheet below for more information about the key elements of the reform
For more information:
🔗https://lnkd.in/eu6RwcaA